ArticleScientific reports2026
Curcumin inhibits glycolysis via EP300 in oral squamous cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Curcumin and Its Derivatives as Anticancer Agents in Head and Neck Cancer: Molecular Mechanisms and Preclinical Evidence.International journal of molecular sciences · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
Curcumin, a natural polyphenolic compound known for its antitumor efficacy, has been shown to modulate glycolytic pathways in various cancers. However, its specific role and underlying mechanism in oral squamous cell carcinoma (OSCC) remain insufficiently explored. This study systematically investigated the impact of curcumin on glycolysis in OSCC cells, with particular focus on EP300, a key epigenetic regulator, as a target of curcumin’s action. Human oral squamous cell carcinoma cell lines (UM-SCC-1 and HSC-3) and normal human oral keratinocytes (HOK) were treated with curcumin at various concentrations. Cell proliferation, clonogenic ability, and migration were assessed using CCK-8, colony formation, and wound-healing assays, respectively. Glycolytic activity was evaluated by measuring glucose uptake and lactate production. An EP300-overexpressing UM-SCC-1 cell line was established via plasmid transfection. Protein-protein interaction (PPI) network analysis through the STRING database identified potential EP300-regulated glycolytic enzymes. Expression levels of EP300 and key glycolytic markers (PKM2, LDHA, GLUT1) were quantified using qRT-PCR and Western blot. Curcumin significantly inhibited proliferation, clonogenic growth, and migration of OSCC cells (UM-SCC-1 and HSC-3) in a concentration-dependent manner. Curcumin treatment markedly reduced glucose uptake and lactate production in OSCC cells, indicating effective suppression of glycolytic activity. At the molecular level, Curcumin downregulated EP300 expression. EP300 overexpression enhanced glycolytic activity and increased the expression of key glycolytic enzymes, including PKM2, LDHA, and GLUT1, and partially reversed the inhibitory effects of curcumin on glycolysis and enzyme expression. Bioinformatic analysis confirmed interactions between EP300 and these glycolytic enzymes. Curcumin suppresses glycolysis in OSCC by modulating EP300 expression and downregulating key glycolytic enzymes such as PKM2, LDHA, and GLUT1. These findings are consistent with curcumin’s potential role as a metabolic modulator in OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.